Literature DB >> 10788619

Cytotoxic activity of a recombinant GnRH-PAP fusion toxin on human tumor cell lines.

J Schlick1, P Dulieu, B Desvoyes, P Adami, J Radom, M Jouvenot.   

Abstract

Pokeweed antiviral protein (PAP), a ribosome-inactivating protein isolated from the leaves of Phytolacca americana, reveals potent antiviral activity against viruses or cytotoxic action against cells once inside the cytoplasm. Therefore PAP is a good candidate to be used as an immunotoxin. We constructed a bacterial expression plasmid encoding PAP as a fusion protein with gonadotropin-releasing hormone (GnRH), a neuropeptide with receptor sites on several gynaecologic tumors. The resulting recombinant toxin was produced in Escherichia coli and accumulated in inclusion bodies. After purification under denaturing conditions, renaturated GnRH-PAP shows an IC(50) of 3 nM on in vitro translation assays and selectively inhibits the growth of the GnRH receptor positive Ishikawa cell line (ID(50) of 15 nM); on the other hand, neither GnRH nor PAP alone had any effect.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10788619     DOI: 10.1016/s0014-5793(00)01469-1

Source DB:  PubMed          Journal:  FEBS Lett        ISSN: 0014-5793            Impact factor:   4.124


  4 in total

1.  Novel LHRH-receptor-targeted cytolytic peptide, EP-100: first-in-human phase I study in patients with advanced LHRH-receptor-expressing solid tumors.

Authors:  Kelly K Curtis; John Sarantopoulos; Donald W Northfelt; Glen J Weiss; Kerry M Barnhart; John K Whisnant; Carola Leuschner; Hector Alila; Mitesh J Borad; Ramesh K Ramanathan
Journal:  Cancer Chemother Pharmacol       Date:  2014-03-08       Impact factor: 3.333

Review 2.  Immunotoxins constructed with ribosome-inactivating proteins and their enhancers: a lethal cocktail with tumor specific efficacy.

Authors:  Roger Gilabert-Oriol; Alexander Weng; Benedicta von Mallinckrodt; Matthias F Melzig; Hendrik Fuchs; Mayank Thakur
Journal:  Curr Pharm Des       Date:  2014       Impact factor: 3.116

Review 3.  Recent Innovations in Peptide Based Targeted Drug Delivery to Cancer Cells.

Authors:  Yosi Gilad; Michael Firer; Gary Gellerman
Journal:  Biomedicines       Date:  2016-05-26

4.  Abrin immunotoxin: targeted cytotoxicity and intracellular trafficking pathway.

Authors:  Sudarshan Gadadhar; Anjali A Karande
Journal:  PLoS One       Date:  2013-03-05       Impact factor: 3.240

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.